Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07017270
PHASE4

Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

Sponsor: Unity Health Toronto

View on ClinicalTrials.gov

Summary

This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2025-11-27

Completion Date

2027-09

Last Updated

2026-06-26

Healthy Volunteers

No

Interventions

DRUG

Semaglutide Pen

Individuals randomized to this arm will take semaglutide once weekly. For participants receiving in-centre hemodialysis, the intervention may be administered during the dialysis session by nursing personnel based on the patient's preference.

Locations (2)

Unity Health Toronto

Toronto, Ontario, Canada

Unity Health Toronto

Toronto, Ontario, Canada